209 : http://clinicalevidence. bmj.com/ceweb/about/knowledge.jsp
210 : The classic general medicine reference for this is Ellis J., Mulligan I., Rowe J., Sackett D.L. Inpatient general medicine is evidence based. -Team, Nuffield Department of Clinical Medicine // Lancet. 1995. 346 (8972) (12 August). P. 407410.
211 : Mayor S. Audit identifies the most read BMJ research papers. BMJ (2007); 334:554-5; Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatoiy drugs: population based nested case-control analysis // BMJ. 2005. 330. P. 1366; Gunnell J., Saperia J., Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRAs safety review // BMJ. 2005. 330. P. 385; Fergusson D. et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials // BMJ. 2005. 330. P. 396.
215 : Iribame . Orphan diseases and adoptive initiatives // JAMA. 2003. 290. P. 116. Francisco A. Drug development for neglected diseases // Lancet. 2002. 360. P. 1102.
218 : Safer D.J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials // J. Nerv. Ment. Dis. 2002. 190. P. 583592.
218 : Modell et al. (1997); Montejo-Gonzalez et al. (1997); Zajecka et al. (1999); Preskom (1997): in Safer, ibid.
220 : Pocock S.J. When (not) to stop a clinical trial for benefit // JAMA. 2005. 294. P. 22282230.
222 : Lexchin J., L.A., Djulbegovic
., Clark . Pharmaceutical industry sponsorship and research outcome and quality // BMJ. 2003. 326. P. 11671170.
222 : Rochon ., Gurwitz J.H., Simms R.W., Fortin P.R., Felson D.T., Minaker K.L., Chalmers T.C. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis // Arch. Intern. Med. 1994. 154 (2) (24 January). P. 157163.
222 : Lexchin J., Bero L.A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review // BMJ. 2003. 326 (7400) (31 May). P. 11671170.
224 B 1995 : Schmidt ., Pittler M.H., Ernst E. Bias in alternative medicine is still rife but is diminishing // BMJ. 323 C7320) (3 November 2001). P. 1071.
224 1998 : Vickers A., Goyal N., Harland R., Rees R. Do certain countries produce only positive results? A systematic review of controlled trials // Control. Clin. Trials. 19 (2) (April 1998). P. 159166.
226 : Dubben H., Beck-Bornholdt H. Systematic review of publication bias in studies on publication bias // BMJ. 2005. 331. P. 433434.
|
|
|
226 : Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy // N. Eng. J. Med. 2008. 358 (3) (17 January). P. 252260.
227 : Tramer M.R., Reynolds D.J.M., Moore R.A., McQuay H. J. Impact of covert duplicate publication on meta-analysis: a case study // BMJ. 1997. 315. P. 635640.
228 : Cowley A.J. et al. // Int. Joum. Card. 1993. 40. P. 161166.
229 : Audit identifies the most read BMJ research papers // BMJ. 334 (17 March 2007). P- 554555.
230 : ScolnickE.M. Email communication to Deborah Shapiro, Alise Reicin and Alan Nies re: Vigor. 9 March 2000. : http://www.vioxxdocuments.com/ Documents/Krumholz_Vioxx/Scolnick2000.pdf
230 : Curfman G.D., Morrissey S., Drazen J.M. Expression of concern reaffirmed // NEJM. 354 (11) (16 March 2006). P. 1193.
231 : Gottlieb S. Firm tried to block report on failure of AIDS vaccine // BMJ. 2000. 321. P. 1173.
232 : Nathan D., Weatherall D. Academia and industry: lessons from the unfortunate events in Toronto // Lancet. 353 (9155)- P- 771772.
233 : Gilbody et al. Benefits and harms of direct to consumer advertising: a systematic review // Qual. Saf. Health Care. 2005. 14. P. 246250; http://qshc.bmj. com/cgi/content/full/14/4/246
